AVA-6103

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameAVA-6103
Drug Alias NameFAP-ExdAVA6103AVA-6103
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionDNA topoisomerase I inhibitorsFibroblast activation protein alpha modulators
TargetsDNA topoisomerase IProlyl endopeptidase FAP
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAvacta Group PLC
China Registration ClassN/A

Develop Information

Active CompaniesAvacta Life Sciences LtdAvacta Group PLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A